RESUMEN

PURPOSE: Tomato is an important source of lycopene, a carotenoid that has been emerging as a natural preventive agent for prostate disease. Moreover, tomato contains other components with a wide range of physiological properties, but their potential beneficial effects on prostatic hyperplasia (PH) during obesity have not been completely established. In this study, we compared the effect of a lipidic extract of tomato saladette (STE) with Serenoa repens (SR) on obese rats with PH. METHODS: Forty-eight Wistar rats were divided in Control (C) and Obese (Ob) treated without (n = 12) and with (n = 36) testosterone enanthate (TE), once a week for 8 weeks to induce PH. After 4 weeks, SR and STE were administered. Biochemical parameters, oxidative stress markers and inflammatory cytokines production were determined. RESULTS: TE increased prostate weight and caused prostatic hyperplasia in C group, and these effects were exacerbated by obesity. SR and STE reverted the increase in prostate weight and hyperplasia caused by TE in C and Ob groups. Obesity increased LDL, TGs, NOx and MAD, but decreased HDLc, GSx, SOD and CAT. SR reverted the effects of obesity, but these were significantly reduced and HDLc increased with STE. Obesity and TE increased TNFα, IL-1ß and IL-6 levels, but these were partially reverted by STE compared with SR. CONCLUSIONS: Excess of fat tissue increases the alterations by PH. STE diminishes these alterations compared with SR, suggesting its beneficial effect to improve prostate function. Whole tomato lipid extract could serve as sole therapy or as an adjunct to pharmacological treatment for PH.

Asunto(s)

Hiperplasia Prostática , Solanum lycopersicum , Masculino , Humanos , Ratas , Animales , Hiperplasia Prostática/tratamiento farmacológico , Hiperplasia , Ratas Wistar , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Testosterona/uso terapéutico , Estrés Oxidativo , Inflamación/tratamiento farmacológico , Obesidad

RESUMEN

El antígeno específico de próstata (PSA, del inglés, Prostate Specific Antigen) es una glicoproteína producida por la próstata, y es el marcador tumoral de mayor uso. Sin embargo, su baja especificidad para diferenciar entre cáncer de próstata y otras alteraciones no malignas, como la hipertrofia benigna de la próstata (HBP) y la prostatitis aguda, limitan su utilidad diagnóstica

---

Prostate Specific Antigen (PSA) is a glycoprotein produced by the prostate and is the most widely used tumor marker. However, its low specificity to differentiate between prostate cancer and other non-malignant conditions, such as benign prostate hypertrophy (BPH) and acute prostatitis, limits its diagnostic utility

Asunto(s)

Antígeno Prostático Específico , Hiperplasia Prostática , Prostatitis , Glicoproteínas de Membrana Plaquetaria , Biomarcadores de Tumor

RESUMEN

We were carried out to investigate the efficacy of Rape (Rapeseed, Brassica napus L.) flower on BPH (benign prostatic hyperplasia) in rats. We found that the extract from Rape flower prevented hyperplasia in testosterone-induced BPH model, the relevant animal model of human BPH. Extract reduced the weight of prostate and induced significantly cell apoptosis in prostate in BPH model. In addition, the extract controlled expression of TGF-ß1 in prostate gland and promoted urinary output in dose-dependence in BPH model. Our data provide that Rape flower may be useful for treatment of BPH

Asunto(s)

Animales , Masculino , Ratas , Hiperplasia Prostática/patología , Eficacia , Brassica napus/anatomía & histología , Flores/clasificación , Testosterona , Extractos Vegetales/análisis , Modelos Animales

RESUMEN

OBJECTIVE: Determining the complications rate and the risk factors associated with early operative and postoperative complications with a bipolar transurethral resection of the prostate at a complex care institution in Colombia. MATERIALS AND METHODS: A mixed cohort study was conducted involving 340 patients diagnosed with benign prostatic hyperplasia who were taken to bipolar transurethral resection of the prostate between 2012 and 2019. Data based on the baseline and perioperative characteristics were collected, and the rate of complications determined up to 30 postoperative days. RESULTS: A total of 67 patients (19.45%) presented perioperative complications of which 17 (25.37%) were previously hospitalized. According to the Clavien Dindo classification, 14.79% were grade I - II: secondary hematuria was the most reported complication and was present in 18 patients (5.22%), followed by complicated urinary tract infections in 16 (4.64%) and dysfunction of the ureterovesical catheter in 6 (1.76%). The risk factors found were surgery during hospitalization (RR:2.23, 95% CI: 1.14 - 4.39), INR (RR: 7.59, IC95%:4.63 - 12.44), duration in days of cysto/irrigation (RR:1.32, CI95%: 1.22 - 1.42) and urethral catheter use (RR: 1.04, CI95%: 1.02 - 1.05). CONCLUSIONS: In this study, the complication rate after bipolar transurethral resection of the prostate was less than 20%. The most frequent complications were grade Iand II according to the Clavien Dindo classification. The risk factors that were found are modifiable, which could reduce postoperative morbidity.

---

OBJETIVO: Determinar la tasa de complicaciones y los factores de riesgo para complicaciones perioperatorias tempranas de la Resección Transuretral de Próstata con bipolar (RTUP-B) en una institución prestadora de servicios de salud de Colombia. MATERIALES Y MÉTODOS: Se realizó un estudio de cohortes mixta en el cual se incluyeron 340 pacientes con diagnóstico de Hiperplasia Prostática Benigna (HPB) que fueron llevados a RTUP-B entre el año 2012y 2019. Se recolectaron datos sobre las características basales y perioperatorias y se determinó la tasa de complicaciones hasta los 30 días postoperatorio. RESULTADOS: 67 pacientes (19,45%) presentaron complicaciones perioperatorias de las cuales 17 (25,37%) fueron intrahospitalarias. Según la clasificación Clavien Dindo el 14,79% fueron complicaciones grado I y II: la hematuria secundaria fue la complicación más reportada en (5,22%), seguida de infecciones del tracto urinario (4,64%) y disfunción de la sonda uretrovesical (1,76%). Los factores de riesgo fueron: estancia hospitalaria previo a la cirugía por cualquier causa (RR:2,23, IC95%: 1,14 ­ 4,39), aumento del valor del INR por unidad (RR: 7,59, IC95%: 4,63 ­ 12,44) y cada día adicional de irrigación vesical (RR: 1,32, IC95%:1,22 ­ 1,42) y sonda vesical (RR: 1,04, IC95%: 1,02­ 1,05). CONCLUSIONES: En este estudio, la tasa de complicaciones después de la RTUP con bipolar fue de meno rdel 20%, siendo las complicaciones grados I y II las más frecuentes. Los factores de riesgo encontrados son modificables lo que podría reducir la morbilidad postoperatoria.

Asunto(s)

Resección Transuretral de la Próstata , Estudios de Cohortes , Colombia/epidemiología , Humanos , Masculino , Próstata , Factores de Riesgo , Resección Transuretral de la Próstata/efectos adversos

RESUMEN

BACKGROUND: The prostate is susceptible to changes in androgen levels, which can play an important role in the development of Benign Prostatic Hyperplasia (BPH). Natural compounds have beneficial properties for organisms and can be an important therapeutic strategy in the treatment of diseases. ß-Caryophyllene (BCP) is a phytocannabinoid present in several medicinal and food plants species and has shown beneficial effects in different organs. However, little is known about its effects on the prostate. The present study seeks to evaluate the effects of exposure to BCP on the morphophysiology of the ventral prostate of adult gerbils supplemented with testosterone. METHODS: Animals were distributed into four groups (n = 8/group): Intact control (C); ß-Caryophyllene (BCP): ß-Caryophyllene (50 mg/kg/day); Testosterone (T): animals received subcutaneous injections of Testosterone Cypionate (3 mg/Kg), on alternate days, for one month and were euthanized 30 days supplementation ended; Testosterone and ß-Caryophyllene (TBCP): animals were exposed to testosterone cypionate (3 mg/Kg) to induce hyperplastic alterations followed by daily BCP (50 mg/kg). Morphological, biometric, immunohistochemical, and serological analyses were performed. RESULTS: Proliferative disorders and inflammatory foci were present in the ventral prostate of all experimental groups. An increase in the multiplicity of benign intraepithelial neoplasm and subepithelial inflammatory foci was observed in T group. The incidence of intraluminal inflammatory foci and microinvasive carcinoma was verified only in the T group. Cellular rearrangement and tissue remodeling occurred in the prostate of groups exposed to phytocannabinoids. A reduction was observed in the frequency of PHH3 and Cox2 markers in the prostatic epithelium of TBCP in comparison with T. A decrease in F4/80 and CD163 positive macrophages were also observed in the prostatic stroma of the TBCP group in comparison with T. The results suggest that BCP had favorable effects on BPH, reducing the proliferation and frequency of some inflammatory cells. CONCLUSION: BCP impacts the tissue remodeling process in the premalignant prostate environment and that the use of this phytocannabinoid can have a promising effect in the handling of BPH.

Asunto(s)

Antiinflamatorios no Esteroideos/administración & dosificación , Proliferación Celular/efectos de los fármacos , Sesquiterpenos Policíclicos/administración & dosificación , Próstata/efectos de los fármacos , Hiperplasia Prostática/inducido químicamente , Hiperplasia Prostática/tratamiento farmacológico , Animales , Proliferación Celular/fisiología , Gerbillinae , Inyecciones Subcutáneas , Masculino , Próstata/patología , Hiperplasia Prostática/patología , Testosterona/administración & dosificación , Testosterona/análogos & derivados , Testosterona/toxicidad , Resultado del Tratamiento

RESUMEN

The human prostate is an androgen-dependent gland where an imbalance in cell proliferation can lead to benign prostatic hyperplasia (BPH), which results in voiding lower urinary tract symptoms in the elderly. In the last decades, novel evidence has suggested that BPH might represent an element into the wide spectrum of disorders conforming the Metabolic Syndrome (MS). The dyslipidemic state and the other atherogenic factors of the MS have been shown to induce, maintain and/or aggravate the pathological growth of different organs, with data regarding the prostate being still limited. We here review the available epidemiological and experimental studies about the association of BPH with dyslipidemias. In particular, we have focused on Oxidized Low-Density Lipoproteins (OxLDL) as a potential trigger for vascular disease and cellular proliferation in atherogenic contexts, analyzing their putative molecular mechanisms, including the induction of specific extracellular vesicles (EVs)-derived miRNAs. In addition to the epidemiological evidence, OxLDL is proposed to play a fundamental role in the upregulation of prostatic cell proliferation by activating the Rho/Akt/p27Kip1 pathway in atherogenic contexts. miR-21, miR-141, miR-143, miR-145, miR-155, and miR-221 would be involved in the transcription of genes related to the proliferative process. Although much remains to be investigated regarding the impact of OxLDL, its receptors, and molecular mechanisms on the prostate, it is clear that EVs and miRNAs represent a promising target for proliferative pathologies of the prostate gland.

Asunto(s)

Aterosclerosis , Vesículas Extracelulares , MicroARNs , Hiperplasia Prostática , Anciano , Humanos , Masculino , MicroARNs/genética

RESUMEN

OBJETIVOS: evaluar la influencia de la modalidad de respuesta (paciente vs. asistido por urólogo) en el cuestionario IPSS (International Prostate Symptom Score) y su relación con la edad y nivel de educación. MATERIALES Y MÉTODOS: Análisis prospectivo de 74 pacientes que acudieron a la consulta de urología por síntomas de Hiperplasia Prostática Benigna (HPB) con o sin tratamiento para su patología y que no hayan completado anteriormente el cuestionario internacional de síntomas prostáticos (IPSS). Los cuestionarios fueron completados en la misma consulta urológica, primero por el paciente y luego con ayuda del urólogo. Se categorizó por edad y nivel de educación. Se evaluó la diferencia entre los puntajes de IPSS obtenidos con la forma autocompletada y con asistencia del urólogo y si esta diferencia estaba relacionada con la edad y con el nivel de educación. Los datos fueron analizados utilizando test no paramétrico para datos apareados de Wilcoxon. RESULTADOS: no se encontró diferencia estadísticamente significativa entre el cuestionario completado por el paciente y el asistido por el urólogo. La media del score total fue de 13,66, y 13,67, respectivamente (p: 0.86). Al analizar los subgrupos, con respecto a la edad y al nivel de educación, tampoco se encontraron diferencias estadísticamente significativas. CONCLUSIÓN: en nuestra población de estudio, el cuestionario IPSS no fue influenciado por la modalidad de administración, tampoco por la edad ni por el nivel de educación.

---

OBJECTIVES: to evaluate the influence of the response modality (patient vs. urologist-assisted) in the IPSS questionnaire (international prostate symptom score) and its relationship with age and education level. MATERIALS AND METHODS: Prospective analysis of 74 patients who came to the urology clinic for symptoms of Benign Prostatic Hyperplasia (BPH) with or without treatment for their pathology and who have not previously completed the international prostate symptoms questionnaire (IPSS). The questionnaires were completed in the same urological consultation, first by the patient and then with the help of the urologist. It was categorized by age and education level. The difference between the IPSS scores obtained with the self-completed form and with the assistance of the urologist and whether this difference was related to age and level of education was evaluated. The data were analyzed using non-parametric test for paired Wilcoxon data. RESULTS: no statistically significant difference was found between the questionnaire completed by the patient and the one assisted by the urologist. The average of the total score was 13.66, and 13.67, respectively (p: 0.86). When analyzing the subgroups, regarding age and level of education, no statistically significant differences were found. CONCLUSION: In our study population, the IPSS questionnaire was not influenced by the modality of administration, neither by age nor by level of education.

Asunto(s)

Humanos , Masculino , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Hiperplasia Prostática , Encuestas y Cuestionarios , Factores de Edad , Escolaridad , Calidad de Vida , Estudios Prospectivos

RESUMEN

INTRODUCTION: Open prostatectomy is an efficacious treatment for Benign Prostatic Hyperplasia (BPH), but its complication rates and risk factors for these might vary due to the characteristics of populations and health systems. OBJECTIVE: To determine the frequency of complications and the risk factors for these, in the first three months after open prostatectomy in a hospital in Medellín (Colombia). METHODS: This is a cohort study in which patients undergoing retropubic open prostatectomy were taken. Medical records were reviewed to obtain demographic, preoperative, and intraoperative data. The main outcome was the incidence of complications in the first three postoperative months and this was divided into early (day 1 to 7 post-surgery) and late (day 8 to 90 post-surgery) complications. Risk factors were determined by estimating Relative Risks (RR). RESULTS: 191 patients with a median age of 70 years were included. The frequency of complications was 34.5%,14.6% occurred early and 19.9% late. Risk factors were dyslipidemia (RR: 2.37, 95% CI: 1.25 to 4.47), irrigation time (RR: 1.31, 95% CI: 1.02 to 1.67) and duration of the postsurgical catheter (RR: 1.07, 95% CI: 1.03 to 1.12); general anesthesia was a protective risk factor compared to spinal (RR: 0.47, 95% CI: 0.24 to 0.91). CONCLUSION: The frequency of complications of open prostatectomy with a retropubic approach was within the figures reported in the literature. The risk factors found could be modifiable and considered for the prevention of adverse outcomes. This study provides an updated basis for future comparisons with alternative treatments for BPH.

---

INTRODUCCIÓN: La prostatectomía abierta es un tratamiento eficaz para la Hiperplasia Prostática Benigna (HPB) pero sus tasas de complicaciones y los factores de riesgo para estas pueden variar por particularidades de las poblaciones y los sistemas de salud. OBJETIVO: Determinar la frecuencia de complicacione sy factores de riesgo en los primeros tres meses postquirúrgicos de la prostatectomía abierta en un hospital de alta complejidad de Medellín (Colombia). MATERIALES Y MÉTODOS: Este es un estudio de cohortes en el cual se tomaron pacientes llevados a prostatectomía abierta retropúbica. Se revisaron las historias clínicas para obtener datos demográficos, prequirúrgicos e intraquirúrgicos. El desenlace principal fue la presentación de complicaciones en los primeros tres meses postquirúrgicos y éste se dividió en complicaciones tempranas (entre el día 1 y 7) y tardías (entre el día 8 y 90). Se determinaron los factores de riesgo mediante la estimación de Riesgos Relativos (RR). RESULTADOS: Se incluyeron 191 pacientes con una mediana de edad de 70 años. La frecuencia de complicaciones fue de 34,5%, 14,6% tempranas y 19,9% tardías. Los factores de riesgo fueron dislipidemia (RR: 2,37, IC95%: 1,25 a 4,47), tiempo de irrigación (RR: 1,31, IC95%: 1,02 a 1,67) y duración de sonda postquirúrgica (RR: 1,07, IC95%: 1,03 a 1,12); la anestesia general fue un factor de riesgo protector en comparación con la raquídea (RR: 0,47, IC95%: 0,24 a 0,91). CONCLUSIONES: La frecuencia de complicaciones de la prostatectomía abierta bajo enfoque retropúbico estuvo dentro de las cifras reportadas en la literatura. Los factores de riesgo encontrados podrían ser modificables  y tenerse en cuenta para la prevención de desenlaces adversos. Con este estudio se sienta una base actualizada para futuras comparaciones con tratamientos alternativos para HPB.

Asunto(s)

Hiperplasia Prostática , Anciano , Estudios de Cohortes , Colombia/epidemiología , Humanos , Hiperplasia , Masculino , Prostatectomía/efectos adversos , Hiperplasia Prostática/cirugía

RESUMEN

BACKGROUND: Prostate cancer (PCa) is the most common malignancy in Mexican men. Serum prostate-specific antigen (PSA) is the usual noninvasive biomarker used for its detection. Its low specificity can increase the number of unnecessary prostate biopsies and the incidence of unpleasant complications for patients. The androgen-receptor gene (AR-CAG) repeat length and the percentage of promoter methylation (PPM) of genes glutathione-S-transferase P1 (GSTP1) and Ras association domain family 1 isoform A (RASSF1A) improve PCa detection. As an option for noninvasive assessment, we evaluated a combined analysis of all these biomarkers. PATIENTS AND METHODS: A total of 186 patients scheduled for biopsy were included in the present study. PSA and AR-CAG repeats were analyzed in blood samples. The PPM of GSTP1 and RASSF1A genes was estimated in prostate tissue and urinary sediment cells (USCs) and plasma DNA using quantitative methylation-specific polymerase chain reaction. The predictive values for PCa and benign prostatic hyperplasia (BPH), logistic regression analysis, receiver operating characteristic curve, and decision curve analysis were used to assess the differential diagnosis. RESULTS: Statistically significant differences between PCa and BPH patients were observed for all biomarkers, with higher positive and negative predictive values when all biomarkers were included in the analysis, attaining USC values of 89.2% and 78.0%, respectively. The differential diagnosis accuracy of PSA (area under the curve, 0.59) increased to 0.70 and 0.68, respectively, when the combined analysis of PPM of RASSF1Aplasma or GSTP1AUSC and AR-CAG repeats was performed. Decision curve analysis showed the utility of the combined analysis to decrease the number of unnecessary biopsies. CONCLUSION: The results showed that combined analysis of the proposed biomarkers in plasma and USCs significantly increased the confidence for the differential diagnosis for PCa and BPH. This noninvasive practice might help in the early detection of PCa and patient follow-up, avoiding to some extent unnecessary prostate biopsies.

Asunto(s)

Metilación de ADN , Gutatión-S-Transferasa pi/genética , Hiperplasia Prostática/diagnóstico , Neoplasias de la Próstata/diagnóstico , Receptores Androgénicos/genética , Repeticiones de Trinucleótidos , Proteínas Supresoras de Tumor/genética , Adulto , Anciano , Anciano de 80 o más Años , Diagnóstico Diferencial , Epigénesis Genética , Humanos , Modelos Logísticos , Masculino , México , Persona de Mediana Edad , Regiones Promotoras Genéticas , Antígeno Prostático Específico/sangre , Hiperplasia Prostática/genética , Hiperplasia Prostática/metabolismo , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/metabolismo , Curva ROC , Sensibilidad y Especificidad

RESUMEN

Arylpiperazines 2-11 were synthesized, and their biological profiles at α1-adrenergic receptors (α1-ARs) assessed by binding assays in CHO cells expressing human cloned subtypes and by functional experiments in isolated rat vas deferens (α1A), spleen (α1B), and aorta (α1D). Modifications at the 1,3-benzodioxole and phenyl phamacophoric units resulted in the identification of a number of potent compounds (moderately selective with respect to the α1b-AR), in binding experiments. Notably, compound 7 (LDT451) showed a subnanomolar pKi of 9.41 towards α1a-AR. An encouragingly lower α1B-potency was a general trend for all the series of compounds, which showed α1A/D over α1B selectivity in functional assays. If adequately optimized, such peculiar selectivity could have relevance for a potential LUTS/BPH therapeutic application.

Asunto(s)

Antagonistas de Receptores Adrenérgicos alfa 1/síntesis química , Antagonistas de Receptores Adrenérgicos alfa 1/farmacología , Diseño de Fármacos , Piperazinas/síntesis química , Piperazinas/farmacología , Receptores Adrenérgicos alfa 1/metabolismo , Antagonistas de Receptores Adrenérgicos alfa 1/química , Antagonistas de Receptores Adrenérgicos alfa 1/metabolismo , Animales , Células CHO , Línea Celular Tumoral , Técnicas de Química Sintética , Clonación Molecular , Cricetinae , Cricetulus , Humanos , Masculino , Simulación del Acoplamiento Molecular , Músculo Liso Vascular/citología , Músculo Liso Vascular/efectos de los fármacos , Piperazinas/química , Piperazinas/metabolismo , Conformación Proteica , Ratas , Receptores Adrenérgicos alfa 1/química , Receptores Adrenérgicos alfa 1/genética , Transducción de Señal/efectos de los fármacos , Relación Estructura-Actividad

RESUMEN

A próstata é um importante sítio de afecções nos cães de meia-idade a senis. Os sintomas geralmentesão transitórios e inespecíficos, e dependem da região prostática acometida, bem como região do corpo afetadapela doença. Já a síndrome da compressão de vasos ilíacos é uma afecção que resulta de disfunção das veiaspélvicas e/ou retroperitoneais, que afetam o sistema venoso da cava inferior. Relata-se o caso de um cão, PastorAlemão, cuja hiperplasia prostática benigna associada a abcesso prostático resultaram na síndrome decompressão das veias ilíacas internas e externas. O animal foi submetido a drenagem cirúrgica e orquiectomia,entretanto veio a óbito após a cirurgia por lesão de reperfusão. Ressalta-se a importância de associar os sintomasde algumas prostatopatias em cães a distúrbios circulatórios sistêmicos, como a síndrome de compressão dasveias ilíacas.

---

The prostate is an important site of infection in middle aged and senile dogs. The symptoms are usuallytransient and non-specific, and depend on the affected prostate region as well as region of the body affected bythe disease. The syndrome of compression of iliac vessels results from a dysfunction of the pelvic and / orretroperitoneal veins, which affect the venous system of the inferior vena cava system. We report the case of adog, German Shepherd, whose benign prostatic hyperplasia associated with prostatic abscess resulted in theiliac vein compression syndrome. The animal underwent surgical drainage and orchiectomy, but died aftersurgery due to reperfusion injury. Thus, it is important to associate the symptoms of some prostatopathies indogs with circulatory disorders, such as the syndrome of compression of the iliac veins.

Asunto(s)

Animales , Perros , Perros/anatomía & histología , Perros/fisiología , Síndrome de May-Thurner/clasificación , Síndrome de May-Thurner/veterinaria

RESUMEN

A próstata é um importante sítio de afecções nos cães de meia-idade a senis. Os sintomas geralmentesão transitórios e inespecíficos, e dependem da região prostática acometida, bem como região do corpo afetadapela doença. Já a síndrome da compressão de vasos ilíacos é uma afecção que resulta de disfunção das veiaspélvicas e/ou retroperitoneais, que afetam o sistema venoso da cava inferior. Relata-se o caso de um cão, PastorAlemão, cuja hiperplasia prostática benigna associada a abcesso prostático resultaram na síndrome decompressão das veias ilíacas internas e externas. O animal foi submetido a drenagem cirúrgica e orquiectomia,entretanto veio a óbito após a cirurgia por lesão de reperfusão. Ressalta-se a importância de associar os sintomasde algumas prostatopatias em cães a distúrbios circulatórios sistêmicos, como a síndrome de compressão dasveias ilíacas.(AU)

---

The prostate is an important site of infection in middle aged and senile dogs. The symptoms are usuallytransient and non-specific, and depend on the affected prostate region as well as region of the body affected bythe disease. The syndrome of compression of iliac vessels results from a dysfunction of the pelvic and / orretroperitoneal veins, which affect the venous system of the inferior vena cava system. We report the case of adog, German Shepherd, whose benign prostatic hyperplasia associated with prostatic abscess resulted in theiliac vein compression syndrome. The animal underwent surgical drainage and orchiectomy, but died aftersurgery due to reperfusion injury. Thus, it is important to associate the symptoms of some prostatopathies indogs with circulatory disorders, such as the syndrome of compression of the iliac veins.(AU)

Asunto(s)

Animales , Perros , Perros/anatomía & histología , Perros/fisiología , Síndrome de May-Thurner/clasificación , Síndrome de May-Thurner/veterinaria

RESUMEN

OBJECTIVE: To evaluate the surgical morbidity and effectiveness in improving symptoms of benign prostatic hyperplasia (BPH), comparing 'button-type' bipolar plasma vaporisation (BTPV) vs transurethral resection of the prostate (TURP). METHODS: We conducted a literature search of published articles until November 2014. Only prospective and randomised studies with comparative data between BTPV and conventional TURP (mono- or bipolar) were included in this review. RESULTS: Six articles were selected for the analyses. In the 871 patients evaluated, 522 underwent TURP and 349 BTPV. There was a tendency for a higher transfusion rate in the TURP group, with two BTPV cases (0.006%) and 16 TURP cases (0.032%) requiring transfusions (P = 0.06). The number of complications was similar between the groups (odds ratio 0.33, 95% confidence interval [CI] 0.8-1.31; P = 0.12; I(2) = 86%). When subdivided by severity, 10.7% (14/131) and 14.6% (52/355) of complications were classified as severe (Clavien 3 or 4) in patients who underwent BTPV and TURP, respectively (P = 0.02). The average duration of indwelling catheterisation was significantly less in patients who underwent BTPV (standardised mean difference [SMD] -0.84; 95% CI -1.54 to 0.14; P = 0.02; I(2) = 81%). Both treatments significantly improved symptoms and the postoperative International Prostate Symptom Score was similar in both groups (SMD 0.09, 95% CI -1.56 to 1.73; P = 0.92). CONCLUSION: BTPV is an effective and safe treatment for BPH. The improvement of urinary symptoms and overall complications are comparable to conventional TURP. However, BTVP appears to be associated with a lower rate of major complications and duration of indwelling catheterisation.

Asunto(s)

Terapia por Láser/métodos , Hiperplasia Prostática/cirugía , Resección Transuretral de la Próstata/métodos , Anciano , Transfusión Sanguínea/estadística & datos numéricos , Catéteres de Permanencia/estadística & datos numéricos , Humanos , Terapia por Láser/efectos adversos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Ensayos Clínicos Controlados Aleatorios como Asunto , Resección Transuretral de la Próstata/efectos adversos , Resultado del Tratamiento

RESUMEN

Sintomas do trato urinário inferior (STUI) representam uma das queixas mais comuns em homens. Diferentes distúrbios da micção podem resultar em STUI. Hipogonadismo é umadoença comum e subdiagnosticada no idoso, podendo estar associado a STUI. O objetivodeste estudo foi avaliar os efeitos da administração crônica da Tadalafila em camundongos hipogonádicos com deficiência crônica de óxido nítrico através de estudo cistométrico in vivo. Para tanto, foi comparado a resposta da Tadalafila em animais castrados(hipogonádicos) e após reposição de testosterona (normogonádicos). Um total de quarenta edois camundongos foram randomizados em seis grupos. Grupo 1(L-NAME): L-NAME(60mg/kg), que é um inibidor da síntese da óxido-nítrico sintase, foi administrado em água debeber. Grupo 2 (DTAD): L-NAME (60mg/kg) + diluente da Tadalafila (goma xantana emanitol). Grupo 3 (TAD): L-NAME (60mg/kg) + Tadalafila diário (4mg/kg). Grupo 4(ORQ): L-NAME (60mg/kg) + orquiectomia...

---

Lower Urinary Tract Symptoms (LUTS) represents one of the most commonly complaints in male. Several voiding disorders can be involved in the pathogenesis of LUTS. Hipogonadism is a common and underdiagnoseddisease in the aging male, usually presenting simultaneously with LUTS. The objective of thisstudy wasto evaluate the cystometric effects of chronic tadalafil administration in castrated micewith nitric oxide cronic deficiency.The results of tadalafiladministration were compared in castrated mice (hypogonadics) and after testosterone replacement (eugonadics). A total of 42 mice were randomized to six groups. Group 1 (L-NAME): L-name (60mg/kg), which is an oxide-nitric sintethase inhibitor, was administrated in drinking water. Group 2 (DTAD): L-name (60mg/kg) + diluent of tadalafil (mannitol and xantane gum). Group 3 (TAD): L-name + daily tadalafil (4mg/kg). Group 4 (ORQ): L-name + orchiectomy...

Asunto(s)

Humanos , Hiperplasia Prostática , Andrógenos , Inhibidores de Fosfodiesterasa

RESUMEN

A fisiopatologia da hiperplasia prostática benigna (HPB) não está totalmente compreendida, no entanto, a diidrotestosterona é o principal hormônio envolvido. Recentemente, o efeito da toxina botulínica A (TB-A) foi investigado, mostrando que esta induz atrofia do parênquima e redução do volume prostático. Com base nisso, este estudo teve como objetivos comparar os efeitos da administração da TB-A com a orquiectomia no tratamento da HPB, além de avaliar os efeitos da TB-A sobre a libido e qualidade do sêmen. Para tanto, 16 cães adultos foram submetidos à castração ou administração de 500U de TB-A, e avaliados durante 16 semanas. A orquiectomia mostrou-se um excelente tratamento, promovendo redução de 80% do volume prostático. Aplicação da TB-A não ocasionou alterações na libido, ereção ou qualidade e características seminais. Por outro lado, reduziu significamente o volume da próstata. Os resultados sugerem que a administração intraprostática de TB-A é um tratamento alternativo efetivo e sem efeitos colaterais para cães destinados a programas de reprodução. No entanto, esta terapia apresenta reduções inferiores do volume prostático, quando comparada com a orquiectomia.

.

---

The pathogenesis of benign prostatic hyperplasia (BPH) is not completely known, however, dihydrotestosterone is a hormone involved in enlargement of the prostate. Recently, the effect of botulinum toxin A (BT-A) was investigated and has shown to induce atrophy of the gland. Based on that, the aims of this study were to compare the effects of administration of BT-A with orchiectomy in the treatment of BPH, in addition to assessing the effects of BT-A on libido and semen quality. Therefore, 16 sexually intact male dogs were submitted to orchiectomy or administration of 500U BT-A, and evaluated for 16 weeks. Orchiectomy presented excellent results, reducing the prostate volume up to 80%. Administration of BT-A did not interfered on libido, erection or semen characteristics. On the other hand, reduced significantly the prostate volume. The results suggest that intraprostatic injection of BT-A is an effective alternative treatment without adverse effects for valuable breeding dogs with BPH. However, this therapy showed lower reduction of prostate volume when compared to orchiectomy.

.

RESUMEN

A fisiopatologia da hiperplasia prostática benigna (HPB) não está totalmente compreendida, no entanto, a diidrotestosterona é o principal hormônio envolvido. Recentemente, o efeito da toxina botulínica A (TB-A) foi investigado, mostrando que esta induz atrofia do parênquima e redução do volume prostático. Com base nisso, este estudo teve como objetivos comparar os efeitos da administração da TB-A com a orquiectomia no tratamento da HPB, além de avaliar os efeitos da TB-A sobre a libido e qualidade do sêmen. Para tanto, 16 cães adultos foram submetidos à castração ou administração de 500U de TB-A, e avaliados durante 16 semanas. A orquiectomia mostrou-se um excelente tratamento, promovendo redução de 80% do volume prostático. Aplicação da TB-A não ocasionou alterações na libido, ereção ou qualidade e características seminais. Por outro lado, reduziu significamente o volume da próstata. Os resultados sugerem que a administração intraprostática de TB-A é um tratamento alternativo efetivo e sem efeitos colaterais para cães destinados a programas de reprodução. No entanto, esta terapia apresenta reduções inferiores do volume prostático, quando comparada com a orquiectomia.(AU)

---

The pathogenesis of benign prostatic hyperplasia (BPH) is not completely known, however, dihydrotestosterone is a hormone involved in enlargement of the prostate. Recently, the effect of botulinum toxin A (BT-A) was investigated and has shown to induce atrophy of the gland. Based on that, the aims of this study were to compare the effects of administration of BT-A with orchiectomy in the treatment of BPH, in addition to assessing the effects of BT-A on libido and semen quality. Therefore, 16 sexually intact male dogs were submitted to orchiectomy or administration of 500U BT-A, and evaluated for 16 weeks. Orchiectomy presented excellent results, reducing the prostate volume up to 80%. Administration of BT-A did not interfered on libido, erection or semen characteristics. On the other hand, reduced significantly the prostate volume. The results suggest that intraprostatic injection of BT-A is an effective alternative treatment without adverse effects for valuable breeding dogs with BPH. However, this therapy showed lower reduction of prostate volume when compared to orchiectomy.(AU)

Asunto(s)

Animales , Perros , Enfermedades de los Perros , Orquiectomía/veterinaria , Hiperplasia Prostática/terapia , Hiperplasia Prostática/veterinaria , Toxinas Botulínicas Tipo A/uso terapéutico

RESUMEN

The aim of this study was to assess the volumetric density (Vv) of the fibronectin in the periurethral region of patients with benign prostatic hyperplasia (BPH) and compare with a control group. Prostatic periurethral tissue samples were obtained from ten patients (age range 65 to 79 years, mean 66) with clinical symptoms of bladder outlet obstruction who had undergone open prostatectomy. The control group samples (periurethral tissue samples from the transitional zone) were collected from prostates obtained during autopsy of accidental death adults of less than 25 years. The volumetric density (Vv) of the fibronectin was determined with stereological methods from 25 random fields per sample using the point-count method with an M-42 grid test system. The quantitative data were analyzed using the Kolmogorov-Smirnov and Mann-Whitney U tests. The Vv in the control and BPH groups was 21.9% ± 1.5% and 29.1% ± 1.2% in the fibronectin, respectively. BPH tissues presented a significant increase of fibronectin in prostatic periurethral region in the transitional zone that may cause lengthening of the prostatic urethra.

Asunto(s)

Fibronectinas/análisis , Próstata/química , Hiperplasia Prostática/metabolismo , Adolescente , Adulto , Anciano , Biomarcadores/análisis , Estudios de Casos y Controles , Humanos , Inmunohistoquímica , Masculino , Próstata/patología , Hiperplasia Prostática/patología , Regulación hacia Arriba , Adulto Joven

RESUMEN

Introduction Published data suggest that patients with acromegaly have an increased prevalence of prostate disorders. Objective To evaluate prostatic disorders in acromegalic patients comparing these results after one year of treatment of acromegaly and with a group of healthy men. Materials and Methods This study was composed of two parts: sectional study comparing patients with healthy controls (baseline) and prospective, longitudinal study (at baseline and after one year of treatment). Forty acromegalic patients were enrolled and evaluated at baseline and after one year with the application of international prostatic symptoms score (IPSS), digital rectal examination, measurements of growth hormone (GH), insulin-like growth factor-I (IGF-I), insulin-like growth factor-binding protein-3 (IGFBP-3), sex hormone-binding globulin (SHBG), prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone, total and free prostate-specific antigen (PSA) levels and prostate ultrasonography (US). Thirty healthy men were selected as control group. Results We stratified patients and controls according to age, considering 40 years-old as cut off. Healthy controls under 40 had IPSS values lower than acromegalic patients. When considering only older patients and controls prostate hyperplasia and structural abnormalities were more frequent in acromegalics. After one year of treatment there was significant decrease in GH, IGF-I and prostate volume in acromegalics over 40 years-old. Conclusions Acromegalics under 40 have more urinary symptoms according to IPSS and above 40 years-old higher frequency of structural changes and increased prostate volume than healthy men. Significant reduction of GH and IGF-I levels during treatment of acromegaly leads to decrease in the prostate volume. .

Asunto(s)

Adulto , Anciano , Humanos , Masculino , Persona de Mediana Edad , Acromegalia/fisiopatología , Acromegalia/terapia , Enfermedades de la Próstata/fisiopatología , Factores de Edad , Acromegalia/metabolismo , Brasil , Estudios de Casos y Controles , Tacto Rectal , Gonadotropinas Hipofisarias/sangre , Hormona del Crecimiento/sangre , /sangre , Factor I del Crecimiento Similar a la Insulina/análisis , Antígeno Prostático Específico/sangre , Enfermedades de la Próstata/metabolismo , Globulina de Unión a Hormona Sexual/análisis , Resultado del Tratamiento , Testosterona/sangre

RESUMEN

Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are two chronic conditions, very common in aged men, that have been associated to inflammatory process. Chemokines and their receptors are recognized as critical mediators of inflammatory responses, they regulate immune cell migration and are implicated in tumor pathogenesis. The impact of two chemokine receptor gene polymorphisms, CCR2-64I (rs1799864) and CCR5-Δ32 (rs333), was evaluated in BPH and PCa. 385 DNA samples (130 BPH, 136 PCa, 119 healthy control) were genotyped. The allele frequencies were similar among control, BPH and PCa groups. Median of serum PSA levels was different between groups: 0.79, 1.45 and 6.91 ng/mL in control, BPH and PCa groups, respectively (all p<0.001). The prostate volume median was 20.00 cm(3) in the control group, thus, lower than BPH (35.35 cm(3)) and PCa (35.80 cm(3)) (both p<0.001), nevertheless no statistical significant difference was observed between BPH and PCa patients (p=0.172). Remarkably, CCR2-64I was a protective factor to PCa when compared with BPH (OR=0.550; 95%CI=0.311-0.975), although the statistically significant difference was lost after correction for multiple comparisons. No significant associations of CCR5-Δ32 variant were observed with BPH, PCa or PCa clinicopathologic status. Our data suggest the influence of CCR2-64I variant in the development of prostate cancer.

Asunto(s)

Polimorfismo Genético , Hiperplasia Prostática/genética , Neoplasias de la Próstata/genética , Receptores CCR2/genética , Receptores CCR5/genética , Adulto , Anciano , Anciano de 80 o más Años , Alelos , Estudios de Casos y Controles , Frecuencia de los Genes , Genotipo , Haplotipos , Humanos , Masculino , Persona de Mediana Edad , Clasificación del Tumor , Estadificación de Neoplasias , Oportunidad Relativa , Neoplasias de la Próstata/patología

RESUMEN

As doenças prostáticas são comuns em cães, desenvolvendo-se após a maturidade sexual. Entre as afecções que acometem a próstata desses animais, a mais frequente é a hiperplasia prostática benigna (HPB). As neoplasias prostáticas, apesar de menos frequentes, são altamente malignas e um diagnóstico tardio está associado a um prognóstico ruim. Os principais métodos de diagnóstico das enfermidades prostáticas em cães incluem um exame clínico detalhado, ultrassonografia, punção aspirativa e biópsia. A utilização de biomarcadores séricos vem sendo estudada como uma maneira de se detectar a doença precocemente, evitando possíveis complicações no quadro clínico dos pacientes. Assim, estudos visando ao diagnóstico precoce de prostatopatias caninas, especialmente o câncer prostático, são cruciais para um tratamento eficaz e melhora da qualidade de vida do animal acometido.

---

Prostatic diseases are common in older dogs, developing after sexual maturity. The most common affecting canine prostate is benign prostatic hyperplasia (BPH). Although less frequent, prostatic neoplasias are highly malignant, and a late diagnosis is closely associated with a poor prognosis. The main methods of diagnosis of the canine prostatic disease include a detailed clinical exam, ultrasound, prostatic fine-needle aspirate and biopsy. Studies towards early diagnosis of this condition are crucial for effective treatment and improvement of quality of life of affected animals. The use of biomarkers has been studied for early detection of the disease, avoiding possible complications in clinical patients.